

RESEARCH PAPER

Luminal 5-HT stimulates colonic bicarbonate secretion in rats

I Kaji^{1,2}, Y Akiba^{1,2,3}, H Said⁴, K Narimatsu¹ and J D Kaunitz^{1,2,3,5}

Departments of ¹Medicine, ⁵Surgery, School of Medicine, ⁴College of Letters and Sciences, University of California, Los Angeles, CA, USA, ²Brentwood Biomedical Research Institute, Los Angeles, CA, USA, and ³Greater Los Angeles Veterans Affairs Healthcare System, CA, USA

Correspondence

Jonathan D. Kaunitz, West Los Angeles VA Medical Center, Bldg. 114, Suite 217, 11301 Wilshire Blvd., Los Angeles, CA 90073, USA. E-mail: jake@ucla.edu

Received 12 December 2014 Revised 16 April 2015 Accepted 9 May 2015

BACKGROUND AND PURPOSE

The bioactive monoamine 5-HT, implicated in the pathogenesis of functional gastrointestinal disorders, is abundantly synthesized and stored in rat proximal colonic mucosa and released to the gut lumen and subepithelial space. Despite much data regarding its expression and function, the effects of luminal 5-HT on colonic anion secretion have not been fully investigated.

EXPERIMENTAL APPROACH

We measured short-circuit current (I_{sc}) as an indicator of ion transport in mucosa-submucosa or mucosa-only preparations of rat proximal colon. Total CO₂ output was measured in vitro and in vivo. Immunohistochemistry was performed to investigate the localization of 5-HT₄, NOS1 and NOS2.

KEY RESULTS

Luminal 5-HT gradually increased the amplitude and sustained the elevation of l_{sc} . Luminal 5-HT-evoked Δl_{sc} was acetazolamide sensitive and HCO₃⁻ dependent, consistent with cytosolic carbonic anhydrase-dependent electrogenic HCO₃⁻ secretion, while not affected by tetrodotoxin (TTX), atropine or indomethacin. Pretreatment with the selective 5-HT₄ antagonist GR113808, but not antagonists for 5-HT₃, 5-HT₆ or 5-HT₇, inhibited luminal 5-HT-evoked Δl_{sc} . Furthermore, luminal cisapride and tegaserod increased l_{sc} to the same extent as did 5-HT in the presence of indomethacin and TTX. Removal of the submucosa or pretreatment with NOS inhibitors enhanced luminal 5-HT-evoked Δl_{sc} , suggesting that NO synthesized in the submucosa suppresses mucosal anion secretion. NOS1 and NOS2 were immunostained in the submucosal neurons and glial cells respectively. Luminal 5-HT-evoked HCO₃⁻ secretion was confirmed *in vivo*, inhibited by co-perfusion of GR113808, but not by ondansetron.

CONCLUSIONS AND IMPLICATIONS

A novel apical 5-HT₄-mediated HCO₃⁻ secretory pathway and an NO-dependent inhibitory mechanism are present in the proximal colon. Luminal 5-HT-evoked HCO₃⁻ secretion may be important for the maintenance of mucosal integrity by regulating luminal pH.

Abbreviations

EC, enterochromaffin; GI, gastrointestinal; L-NIO, N-iminoethyl-L-ornithine; NPA, N^{ω} -propyl-L-arginine; SCFA, short-chain fatty acid; SERT, 5-HT uptake transporter; SNAP, S-nitroso-N-acetylpenicillamine; SNP, sodium nitroprusside; SSRI, selective serotonin reuptake inhibitor; TPH, tryptophan hydroxylase; TTX, tetrodotoxin.



Tables of Links

TARGETS Ligand-gated ion channels^a 5-HT3 receptor GPCRsb 5-HT₄ receptor 5-HT₆ receptor 5-HT₇ receptor Ion channels CFTR anion channel ENaC sodium channel **Transporters**^d DRA, SLC26A3 NKCC1, SLC12A2 SERT (SLC6A4) Enzymes^e NOS COX

LIGANDS
5-HT
1400W
Acetazolamide
Amiloride
Atropine
Bumetanide
Cisapride
Fluoxetine
GR113808
Indomethacin
L-NAME
NO
Ondansetron
SB258719
Tegaserod
ТΤΧ

These Tables list key protein targets and ligands in this article which are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Pawson *et al.*, 2014) and are permanently archived in the Concise Guide to PHARMACOLOGY 2013/14 (*ab.c.d.e*Alexander *et al.*, 2013a,b,c,d,e).

Introduction

5-HT (serotonin) is one of the most important signalling molecules affecting gastrointestinal (GI) function due to its many contributions to physiological and pathophysiological conditions through its seven receptor subtypes and reuptake transporters (Gershon and Tack, 2007). More than 98% of 5-HT in humans is synthesized by enterochromaffin (EC) cells by the rate-limiting enzyme tryptophan hydroxylase (TPH)-1, followed by L-amino acid decarboxylase, whereas the remaining 2% is produced in CNS by TPH-2. The highest percentage of enteroendocrine cells is composed of EC cells (Sjölund et al., 1983), with EC cell density highest in the proximal colon in rats (Glisic et al., 2006). Luminal release of 5-HT in relation to increased luminal pressure and peristalsis was first reported in 1958 in guinea pig and rabbit small intestine (Bülbring and Lin, 1958). Moreover, mucosal stroking, luminal acid or vagal nerve stimulation released 5-HT from EC cells into the lumen more than into the circulation (Ahlman et al., 1981a,b; Kellum et al., 1983; 1999), suggesting that luminal 5-HT release is functionally regulated. In the rat colon, luminal 5-HT concentration is elevated by luminal perfusion with short-chain fatty acids (SCFAs) or by an increase in luminal pressure (Fukumoto et al., 2003; Tsukamoto et al., 2007). Yet, despite these many observations, the effects of luminal 5-HT on colonic ion secretion have rarely been investigated. In the mouse distal colon, the 5-HT₄ receptor is expressed in colonic epithelial cells; luminal application of the 5-HT₄ agonist tegaserod increased short-circuit current (I_{sc}) , inhibited by tetrodotoxin (TTX) or the 5-HT₄ antagonist GR113808 (Hoffman et al., 2012). As 5-HT is also

biosynthesized in plants as a signal transmitter from tryptophan by non-mammalian pathways (Kang *et al.*, 2007), some common foodstuffs such as tomatoes, corn, rice and bananas contain considerable amounts of 5-HT (30–140 µg·g⁻¹) (Badria, 2002; Ly *et al.*, 2008), suggesting that the GI mucosa is frequently exposed to measurable endogenous and exogenous concentrations of 5-HT. As 5-HT is implicated in the generation of functional GI symptoms (Cremon *et al.*, 2011), a knowledge of the actions of luminal 5-HT is important for understanding GI physiology and functional disorders.

NO is a gaseous signal molecule produced by a variety of cell types with three NOS isozymes: NOS1 (also known as brain NOS or neuronal NOS), NOS2 (inducible NOS) or NOS3 (endothelial NOS). Released NO affects mucosal secretory function either as a pro- or anti-secretory modulator. Serotonergic Cl⁻ secretion is partially mediated by NO-dependent pathways (Kadowaki et al., 1996; Stoner et al., 2000), involved in the stimulation of anion secretion via neural and COX activation, as studied in Ussing-chambered rat colon (Tamai and Gaginella, 1993; Wilson et al., 1993). Nevertheless, cAMP-dependent secretion is attenuated by NOS2-dependent NO accumulation (Asfaha et al., 1999; Freeman and MacNaughton, 2000; MacEachern et al., 2011). Furthermore, nicotinergic Cl⁻ secretion is suppressed by endogenous NO, which is tonically derived from myenteric ganglia in mouse distal colon (MacEachern et al., 2011).

Here, we show that luminal 5-HT increased electrogenic HCO_3^- secretion via 5-HT₄ receptors in rat proximal colon *in vivo* and *in vitro*. The luminal 5-HT-induced I_{sc} increase was independent of neural or COX activity, and was enhanced by removal of the submucosal layer or by NOS inhibition. Our



findings are consistent with the presence of a novel apical $5\text{-HT}_4\text{-mediated HCO}_3^-$ secretory pathway and with an NO-dependent anti-secretory mechanism for Cl^- secretion in rat proximal colon.

Methods

Animals

All animal care and experimental studies were performed with approval of the Veterans Affairs Institutional Animal Care and Use Committee. All studies involving animals are reported in accordance with the ARRIVE guidelines for reporting experiments involving animals (Kilkenny *et al.*, 2010; McGrath *et al.*, 2010). A total of 166 animals were used in the experiments described here. Male Sprague-Dawley rats weighing 200–250 g (Harlan, San Diego, CA, USA) were fed with a pellet diet and water *ad libitum*. Rats were fasted overnight in wire-bottomed cages with free access to water before the experiments.

Tissue preparation for Ussing chamber studies

Rats were anaesthetized by isoflurane and killed by exsanguination. Mucosa-submucosa preparations were fashioned from proximal, mid and distal colon as described previously (Kaji et al., 2012). The colonic segments, opened along the mesenteric border, were stripped off the muscle layers with fine forceps under a stereomicroscope in ice-cold Krebs-Ringer buffer. Submucosal layers were further removed for some experiments. Two preparations were made from each segment by dividing longitudinally, and mounted between two hemichambers with an aperture with area = 0.3 cm² (Physiologic Instruments, San Diego, CA, USA). A matched pair of preparations was used for the control and experimental groups, with combinations of three or more groups used for multiple comparisons. Removal of muscle layers or submucosal layers was confirmed by histological examination of frozen sections obtained from chambered mucosa after completion of the Ussing chamber studies.

I_{sc} and total CO₂ output measurements in Ussing chambers

The chambers were bathed with serosal and luminal bathing solutions in a volume of 4 mL each, maintained at 37°C with a water-recirculating heating system. The bathing Krebs-Ringer solution contained (in mM) 117 NaCl, 4.7 KCl, 1.2 MgCl₂, 1.2 NaH₂PO₄, 2.5 CaCl₂, 25 NaHCO₃, 11 glucose, and bubbled with 95% O₂-5% CO₂ to maintain pH at 7.4. For HCO₃-free conditions, NaHCO₃ was replaced with NaCl and acetazolamide (0.2 mM) was added into the serosal and luminal baths bubbled with 100% O₂. For Cl⁻-free solutions, NaCl, KCl and CaCl2 were replaced with sodium gluconate, potassium gluconate and 8 mM calcium gluconate respectively. The tissues were short-circuited by a voltage clamp (Physiologic Instruments) at zero potential automatically with compensation for solution resistance. I_{sc} and tissue conductance (G_t) were determined every 2 s and recorded by the DataQ system (Physiologic Instruments). Positive values for I_{sc} indicate a negative electrical charge flux from serosal \rightarrow

luminal bath indicating anion secretion or cation absorption. Tissues were stabilized for 50 min before 5-HT or other drugs were added. DMSO (<0.3%) in the bathing solution did not affect basal I_{sc} .

To correlate HCO₃⁻ secretion with I_{sc} changes, total CO₂ content in the luminal bathing solutions was measured using a CO2 electrode (Lazar Research Laboratories, Los Angeles, CA, USA) as previously described (Akiba et al., 2001). As luminally applied 5-HT hydrochloride (100 µM) and acetazolamide (0.2 mM) are acidic, the pH-stat method with normal saline in the luminal bath cannot accurately measure titratable alkalinity, total CO2 content changes in the luminal bath were measured as luminal HCO₃⁻ output. The proximal colonic tissues were mounted in Ussing chambers as described above, with pH 7.4 Krebs buffer containing (in mM) 136 NaCl, 2.6 KCl, 1.8 CaCl₂, 10 HEPES and 10 glucose in the luminal bath with 100% O2 bubbling. Luminal pH was continuously monitored with a pH electrode (Radiometer Analytical, Lyon, France). After \sim 30 min to ensure I_{sc} stabilization, time was set as t = 0 min. One-half millilitres of the luminal bathing solution was collected and replaced with prewarmed, O2 bubbled Krebs buffer every 5 min. Each sample was added to 4.5 mL of 0.1 M citrate buffer (pH 4.5) to convert free HCO₃⁻ to CO₂, which was measured by a CO₂ electrode (Akiba et al., 2001). As the secreted HCO₃⁻ was accumulated in the luminal solution, basal total CO₂ content averaged from basal period for 10 min was subtracted from total CO2 content at each time point. Luminal HCO3output change was expressed as $\Delta total$ CO₂ output $(\mu \text{mol} \cdot \text{min}^{-1} \cdot \text{cm}^{-2}).$

*Effect of 5-HT on colonic HCO*₃⁻ *secretion* in vivo

Colonic loops were prepared and perfused according to the modified method for duodenal perfusion (Akiba et al., 2007; 2009). Under isoflurane anaesthesia (2%), the abdomen was incised, the caecum and proximal colon were exposed, and a 0.5 cm incision was made in the proximal colonic wall 0.5 cm caudal to the caecum using a thermal cautery. A polyethylene tube (outer diameter 5 mm, inner 3 mm) was inserted through the incision and positioned until it was 0.5 cm caudal to the incision, where it was secured with a nylon ligature. The distal portion of the proximal colon was ligated proximal to the mid colon followed by filling the colonic loop with 1 mL saline pre-warmed at 37°C. The distal portion was then incised, and another polyethylene tube (outer 7 mm, inner 5 mm) was inserted through the incision and sutured into place. To prevent colonic wall ischaemia, sutures were placed between serosal arteries and branches of mesenteric arteries. The resultant closed proximal colonic loop (perfused length 2 cm) was perfused with pH 7.0 Krebs buffer by using a peristaltic pump at 1 mL·min⁻¹. The perfusate, bubbled with 100% O₂, was kept at 37°C using a heated stirrer. To eliminate buffering by added compounds, which would over- or underestimate the pH-stat titration volume, flow-through pH and CO2 electrodes (Lazar Research Laboratories) were connected to the perfusion loop, where pH and CO₂ concentration ([CO₂]) were simultaneously and continuously measured. As the input (perfusate) $[CO_2]$ is ≈ 0 , the effluent [CO₂] and pH were used to calculate the total CO₂

output equivalent to the secreted $\mathrm{HCO_3}^-$. After stabilization following continuous perfusion of pH 7.0 Krebs buffer for about 30 min, the time was set as t=0. The colonic loop was then perfused with pH 7.0 Krebs buffer from t=0 min to t=10 min (basal period). The perfusate was then changed to pH 7.0 Krebs buffer containing 5-HT (pH 7.0) from t=10 to 35 min (experiment period), with or without inhibitors. At t=10 min, the system was gently flushed so as to rapidly change the composition of the perfusate. Colonic $\mathrm{HCO_3}^-$ secretion was expressed as total $\mathrm{CO_2}$ output ($\mu\mathrm{mol\cdot min^{-1}\cdot cm^{-1}}$) calculated from the measured pH and [$\mathrm{CO_2}$] in the effluent solution as previously reported (Akiba et al., 2007).

Real-time RT-PCR and immunohistochemistry

Expression of 5-HT $_3$ and 5-HT $_4$ receptors in the colonic mucosa or submucosa was analysed by real-time RT-PCR as previously described (Akiba *et al.*, 2009). The PCR primers of rat 5-HT $_3$ were sense (5'-tgctgaggctgtcagatcac) and antisense (5'-ccacgtccacaaactcattg), giving rise to a predicted 285 bp PCR product; the primers of 5-HT $_4$ were sense (5'-gagaccaaagcagccaagac-3') and antisense (5'-aggaaggcacgtctgaaaga-3'), a predicted 212 bp product. β-actin was used as an internal control. The expression level was described as fold induction per 10^3 copies of β-actin by ΔC_t method.

In order to investigate the localization of 5-HT₄ receptors in the colonic mucosa, the proximal colonic segments were fixed with methanol for 10 min, followed by Zamboni's fixative overnight. Cryostat sections (up to 8 μ m thick) were reacted with rabbit anti-5-HT₄ receptor antibody against extracellular epitope at 1:300 (Alomone Labs, Jerusalem, Israel), followed by incubation with the corresponding Alexa 488 secondary antibody (Molecular Probes, Grand Island, NY, USA). Negative controls were processed identically with the omission of the primary antibody or by incubation with primary antibody pre-absorbed with the immunizing peptide (30 μ mL⁻¹) overnight at 4°C.

Whole-mount preparations of submucosal plexus were made in order to determine the location of NOS isoforms in the proximal colon. The submucosal layers of rat proximal colon were isolated and pinned on a silicone-filled Petri dish and immersed in Zamboni's fixative overnight at 4°C. The fixed submucosal preparations were washed in PBS to remove picric acid. Non-specific immunoreactions were blocked by preincubation with 0.5% normal donkey serum in PBS for 1 h at room temperature. Pre-blocked tissues were reacted with primary antibodies for NOS1 (ab72428; Abcam, Cambridge, MA, USA), NOS2 (sc650; Santa Cruz Biotechnology, Santa Cruz, CA, USA), PGP9.5 (ab8189; Abcam) or glial fibrillary acidic protein (GFAP; GFAP-Go-Af1000; Frontier Institute Co., Ltd, Sapporo, Japan) diluted at 1:200 by blocking solution for 24 h at 4°C. After washing in PBS, fluorescenceconjugated antibodies were incubated for 2 h at room temperature. The tissues were counterstained with 4',6diamidino-2-phenylindole and mounted with EverBrite mounting medium (Biotium, Hayward, CA, USA). Immunofluorescence was imaged and captured using a confocal laser microscope (LSM710; Carl Zeiss GmbH, Jena, Germany).

Data analysis

Values are expressed as mean \pm SE, with n indicating the number of animals. Statistical analysis was performed in GraphPad Prism 6 (La Jolla, CA, USA) using Student's t-test between two groups. In three or more groups, one- or two-way anova was used based on the experimental design, followed by multiple comparisons with Fischer's least significant difference $post\ hoc$ test. Differences were considered significant when P values < 0.05.

Materials

1400W was purchased from Cayman Chemical (Ann Arbor, MI, USA). GR113808, fluoxetine, S-nitroso-Nacetylpenicillamine (SNAP), BGC20-761, SB258719, N-iminoethyl-L-ornithine (L-NIO) and N^{ω} -propyl-L-arginine (NPA) were from Tocris Bioscience (Ellisville, MO, USA). 5-HT, ondansetron and other chemicals were from Sigma Chemical (St. Louis, MO, USA). 5-HT was dissolved in distilled water before each experiment. For stock solutions, indomethacin was dissolved in ethanol; TTX, 1400W and N^G-nitro-Larginine methyl ester (L-NAME) were dissolved in distilled water; GR113808, ondansetron, fluoxetine, bumetanide and acetazolamide were dissolved in DMSO. Chemical concentrations used in this study were typically chosen based on concentrations used in comparable published studies.

Results


Effect of luminal 5-HT on I_{sc} in rat proximal colon


In Ussing-chambered mucosa-submucosa preparations, luminal application of 5-HT (100 μ M) increased I_{sc} , accompanied by G_t increase, peaking within 5 min and sustained for more than 30 min (Figure 1A). Pretreatment with indomethacin (10 μ M) significantly decreased basal I_{sc} from 59.0 \pm 8.55 to $43.6 \pm 3.53 \,\mu\text{A}\cdot\text{cm}^{-2}$ ($P < 0.05 \,\text{vs.}$ untreated tissues), but did not alter the luminal 5-HT-evoked I_{sc} increase. The combination of indomethacin and TTX (1 µM) further decreased the basal I_{sc} to 32.6 \pm 2.21 μ A·cm⁻² (P < 0.05 vs. untreated tissues), but did not affect the response to 5-HT. Pretreatment with atropine (10 µM) did not change basal and luminal 5-HTevoked ΔI_{sc} , indicating that COX-dependent, cholinergic or TTX-sensitive pathways were not involved in the increase in $I_{\rm sc}$ in response to luminal 5-HT (Figure 1B). To minimize the effects of endogenous prostaglandins and of neural reflexes, subsequent experiments were performed in the presence of indomethacin and TTX.

Ionic basis of luminal 5-HT-evoked I_{sc} *increases*

We next investigated the ionic components of the $I_{\rm sc}$ response to 5-HT with the inhibitor of the NKCC1 ion transporter, bumetanide, and the carbonic anhydrase inhibitor, acetazolamide. As shown in Figure 2A, the $I_{\rm sc}$ response to luminal 5-HT was decreased by serosal addition of bumetanide (0.1 mM) and further decreased by the addition of acetazolamide (0.2 mM) into the serosal and luminal baths. Bumetanide and acetazolamide decreased the $I_{\rm sc}$ response to 5-HT by 19 and







Luminal 5-HT-evoked increases in I_{sc} in rat proximal colon. (A) Representative I_{sc} and G_t traces illustrated that luminal (M) 5-HT (100 μ M) gradually and simultaneously increased I_{sc} and G_t . (B) Luminal 5-HT-evoked ΔI_{sc} was determined in the presence or absence of indomethacin (IND, 10 μ M) added to the serosal and luminal bathing solutions with TTX (1 μ M) or atropine (Atr, 10 μ M) added to the serosal bath. Inhibitors were added immediately after mounting tissues in the Ussing chamber and incubated during stabilization period. There was no significant difference between groups as determined by one-way ANOVA (F = 0.55, P = 0.66). n = 5.

58% respectively (Figure 2B). Benzolamide (Akiba *et al.*, 2006), an ecto-carbonic anhydrase inhibitor, had no effect on 5-HT-evoked $I_{\rm sc}$ changes (data not shown), suggesting that the inhibitory effect of acetazolamide on the $I_{\rm sc}$ response to 5-HT is due to the inhibition of cytosolic carbonic anhydrase activity. Bumetanide and acetazolamide inhibited the $I_{\rm sc}$ response independently of their order of application, indicating that the 5-HT-evoked increase in $I_{\rm sc}$ is due to anion secretion and that cytosolic HCO_3^- production is the principal component (as compared with basolateral NKCC-mediated Cl⁻ uptake) of the 5-HT-evoked $I_{\rm sc}$ increase in rat proximal colon.

Removal of Cl- from both bathing solutions decreased basal I_{sc} and G_t by 32.9 \pm 5.45 $\mu \text{A} \cdot \text{cm}^{-2}$ and 12.0 \pm 1.52 mS·cm⁻², respectively (n = 5), indicating that the basal I_{sc} is generated by electrogenic Cl⁻ secretion in rat proximal colon. The decrease of basal I_{sc} ($\Delta I_{sc} = -9.7 \pm 3.92 \,\mu\text{A}\cdot\text{cm}^{-2}$) and G_t (ΔG_t = -1.1 ± 0.38 mS·cm⁻²) in HCO₃⁻-free conditions was significantly smaller than in Cl⁻-free buffer (P < 0.05, n = 5), indicating that electrogenic HCO₃⁻ transport contributed less to basal I_{sc} and G_t . The absence of Cl⁻ or HCO₃⁻ significantly reduced the I_{sc} responses to luminal 5-HT by 62 or 68% respectively (Figure 2C). These results suggest that the increase of I_{sc} in response to 5-HT is due either to electrogenic HCO₃⁻ or Cl⁻ secretion. Nonetheless, increased *I*_{sc} in response to carbachol was due mostly to Cl- rather than HCO₃- secretion, consistent with the known Ca²⁺-mediated Cl⁻ secretory pathway in response to cholinergic stimuli (Figure 2D). These results suggest that 5-HT-evoked I_{sc} is principally generated by HCO₃⁻ secretion, in comparison to the predominant Cl⁻ secretion generated by carbachol.

Effect of luminal 5-HT on HCO₃⁻ secretion in parallel with increase in I_{sc}

In order to confirm HCO_3^- secretion in response to luminal 5-HT, parallel measurements of I_{sc} and total CO_2 output were performed as shown in Figure 3. With HCO_3^- -free HEPES buffer in the luminal bath, luminal 5-HT increased I_{sc} as the

same extent as Krebs–Ringer buffer described in Figure 1. The Δ total CO₂ output was increased commensurately with the increase of $I_{\rm sc}$. Serosal addition of bumetanide slightly decreased $I_{\rm sc}$, with no effect on Δ total CO₂ output, whereas luminal and serosal addition of acetazolamide dramatically decreased $I_{\rm sc}$, concomitant with remarkable decrease of Δ total CO₂ output. These results confirmed that the luminal 5-HT-induced increase in $I_{\rm sc}$ was equivalent to luminal HCO₃⁻ secretion, and that acetazolamide-sensitive $I_{\rm sc}$ changes following luminal 5-HT-induced increase of $I_{\rm sc}$ represented the acetazolamide-sensitive HCO₃⁻ secretion into the lumen.

Effect of 5-HT receptor antagonists on luminal 5-HT-evoked anion secretion

In rat colon, serosal 5-HT-evoked secretion is mediated by a ligand-gated ion channel 5-HT₃ receptor and a G₅-coupled 5-HT₄ receptor (Bunce et al., 1991; Ning et al., 2004; Day et al., 2005; Yang et al., 2010). We therefore examined the effect of the selective 5-HT₃ antagonist ondansetron (10 μM) or the selective 5-HT₄ antagonist GR113808 (1 μM) on luminal 5-HT-evoked secretion. Pretreatment with luminal ondansetron or GR113808 did not change the basal I_{sc} or G_t . GR113808, but not ondansetron, significantly reduced the response to luminal 5-HT by 73% (Figure 4A). The 5-HT₆ and 5-HT₇ receptor subtypes are also identified as G_s-coupled receptors (Baker et al., 1998; Zhang et al., 2003). The selective 5-HT_6 antagonist BGC20-761 (1 μM) or the selective 5-HT_7 antagonist SB258719 (10 µM) did not affect 5-HT-evoked secretion (Figure 4A). As K_i values of BGC20-761 and SB258719 are 20 and 30 nM, respectively, and SB258719 is 100-fold more selective for 5-HT₇ than for other receptor subtypes (Forbes et al., 1998), these concentrations are likely to be ideal for selective inhibition of each target receptor. We also confirmed that GR113808 inhibited the response to luminal 5-HT in a dose-dependent manner (Figure 4B), indicating that luminal 5-HT-evoked anion secretion is mainly mediated by luminal 5-HT₄ receptors.




Figure 2

Contribution of anion secretion to luminal 5-HT-evoked I_{sc} increase. (A) A representative time course of I_{sc} illustrated that luminal 5-HT increased I_{sc} over a sustained period. Further serosal addition (S) of bumetanide followed by acetazolamide into the serosal and luminal baths (SM) decreased 5-HT-evoked I_{sc} . (B) Inhibitory rate of 5-HT-evoked ΔI_{sc} by bumetanide or acetazolamide. The application order of inhibitors was randomized. *P < 0.05. P = 6. (C, D) The effect of Cl⁻ or HCO₃⁻ depletion on 5-HT-evoked ΔI_{sc} (C) and on CCh-evoked ΔI_{sc} (D). After the stabilization period, the serosal and luminal bathing solutions were replaced with Cl⁻-free or HCO₃⁻-free buffers. Fifteen minutes after the replacement, 5-HT (100 μ M) was added to the luminal bath followed by CCh (10 μ M) into the serosal bath. *P < 0.05 versus each control group (open bar) determined by one-way ANOVA (C, P = 7.82; D, P = 6.36); P = 6.36); P = 6.36

Effect of luminal 5-HT₄ receptor agonists on I_{sc} in rat proximal colon

To further confirm the contribution of 5-HT₄ receptors to colonic anion secretion, we investigated the effects of the selective 5-HT₄ agonists cisapride and tegaserod in the presence of indomethacin and TTX. Luminal application of cisapride (1–100 μ M) dose dependently increased I_{sc} , temporally resembling the response to luminal 5-HT. Pretreatment with luminal GR113808 (1 μ M) completely abolished the response to luminal cisapride (100 μ M) (Figure 5A). Luminal application of tegaserod (0.1–10 μ M) also dose-dependently increased and sustained I_{sc} (Figure 5B).

Effect of a selective 5-HT uptake inhibitor (SSRI) on 5-HT-evoked secretion


The 5-HT transporter (SERT), expressed in intestinal epithelial cells, locally affects the mucosal actions of 5-HT (Wade *et al.*,

1996). To test the hypothesis that inhibition of SERT would modulate luminal 5-HT-evoked secretion, we used the fluoxetine, which inhibits 5-HT uptake in the intestinal Caco2 cell line with $IC_{50}=0.02~\mu M$ (Martel *et al.*, 2003). Luminal or serosal pretreatment with fluoxetine (0.1 μM) enhanced 5-HT-evoked anion secretion (Figure 6), consistent with the presence of the 5-HT transporter on the apical and basolateral membrane of colonocytes.

Secretory response to luminal 5-HT in mucosal preparations


In muscle- and submucosa-stripped mucosal preparations, which excluded submucosal and myenteric plexuses, the serosal addition of TTX (1 μ M) decreased basal I_{sc} by 6.7 \pm 1.63 μ A·cm⁻² (n = 5), indicating that neural reflexes remain in the lamina propria, consistent with previous reports (Bridges *et al.*, 1986). In the presence of indomethacin and TTX, basal





Effect of 5-HT, bumetanide and acetazolamide on HCO_3^- secretion in Ussing chambers. Changes of I_{sc} and total CO_2 output into the luminal bath were simultaneously measured and results were described as the differences (Δ) from the averaged values at t=0-10 min. After 10 min basal period (t=0-10 min), 5-HT (t=0 m) was added to luminal bath at t=10 min, followed by bumetanide (t=00.1 mM) to serosal bath at t=25 min and acetazolamide (t=00.2 mM) to luminal and serosal baths at t=35 min. A representative time course of t=00 and means t=01 section t=02 output (t=03) showed that luminal 5-HT increased t=03 and total t=04 output in parallel, in an acetazolamide-sensitive manner. t=05

 I_{sc} (37.7 ± 2.18 μ A·cm⁻², n = 33) and G_{t} (25.3 ± 1.38 mS·cm⁻²) were similar to those in mucosa-submucosa preparations (I_{sc} , 30.2 ± 1.75 μ A·cm⁻² and G_{t} , 22.6 ± 1.29 mS·cm⁻²; n = 39), with no significant difference in basal potential difference and resistance. The increase in I_{sc} induced by luminal 5-HT was significantly larger in mucosal preparations than that in mucosa-submucosa preparations at all 5-HT doses tested (Figure 7A). Luminal 5-HT-evoked I_{sc} in mucosal preparations was sustained, and rapidly decreased by addition of bumetanide (0.1 mM) followed by acetazolamide (0.2 mM) (Figure 7B). The acetazolamide-sensitive I_{sc} component (38%) was significantly smaller, whereas the bumetanide-sensitive I_{sc} component of the response to 5-HT in mucosal preparations (44%) was larger than that in mucosa-submucosa preparations (Figure 7C). Thus, the calculated ΔI_{sc} value of the







Figure 4

Effect of selective 5-HT receptor antagonists on 5-HT-evoked l_{sc} increase. (A) Luminal 5-HT-evoked Δl_{sc} was measured in the presence or absence of the antagonist for 5-HT $_3$ ondansetron (10 μ M), for 5-HT $_4$ GR113808 (GR, 1 μ M), for 5-HT $_6$ BGC20-761 (BGC, 1 μ M) or for 5-HT $_7$ SB 258719 (SB, 10 μ M). The antagonist was added into the luminal bath 10 min before the luminal application of 5-HT (100 μ M). n=5 for each inhibitor and n=8 for control. *P<0.05 versus 5-HT group by one-way ANOVA (F=6.81). (B) Dose-dependent inhibition of luminal 5-HT $_4$ antagonist of the response to 5-HT. Each concentration of GR113808 was individually added into the luminal bath 10 min before the addition of 5-HT (100 μ M). n=6.*P<0.05 versus 5-HT group by one-way ANOVA (F=3.37).

bumetanide-sensitive component corresponded to the difference of the responses to 5-HT between the mucosal and mucosa-submucosal preparations (Figure 7D). There was no difference in the magnitude of the acetazolamide-sensitive components between the mucosal preparations and the mucosa-submucosa preparations.

We also investigated the effect of bumetanide on basal I_{sc} in mucosa-submucosa or mucosal preparations. After the stabilization period, the serosal application of bumetanide (0.1 mM) did not change in the mucosa-submucosa preparations, whereas basal I_{sc} was decreased in the mucosal






Figure 5

Effect of luminal 5-HT₄ receptor agonists on I_{sc} . (A, B) Each concentration of cisapride (A) or tegaserod (B) was individually added into the luminal bath (M) and I_{sc} changes were measured in the presence of TTX and indomethacin. Both cisapride (F = 13.2 by one-way ANOVA) and tegaserod (F = 47.4) increased I_{sc} in a dose-dependent manner. Pretreatment with luminal GR113808 (1 μ M) abolished the response to cisapride (100 μ M). *P < 0.05. P = 5.




Figure 6

Effect of an SSRI on 5-HT-evoked I_{sc} increase. Fluoxetine (0.1 μ M) was added into the luminal (M) or serosal (S) bath 10 min before the luminal application of 5-HT (100 μ M). n=8. There were significant differences among groups (F=3.84 by one-way ANOVA). *P<0.05 versus 5-HT group.

preparations (ΔI_{sc} , $-8.0 \pm 2.9 \,\mu\text{A}\cdot\text{cm}^{-2}$; n=6). These results support the hypothesis that the submucosa suppresses basal and luminal 5-HT-evoked NKCC1-sensitive Cl⁻ secretion.

Involvement of NO signalling in 5-HT-evoked anion secretion

We hypothesized that NO may mediate the secretory inhibition attributable to the submucosa. Serosal pretreatment with the non-selective NOS inhibitor L-NAME (0.1 mM) did not alter basal $I_{\rm sc}$ either in mucosa-submucosa or mucosa-only preparations. L-NAME significantly enhanced 5-HT-evoked secretion in mucosa-submucosa preparations (Figure 8A), to the same extent as that in mucosal preparations (Figure 8B). Conversely, L-NAME treatment did not alter the response to


luminal 5-HT in mucosa-only preparations (Figure 8B), suggesting that NO generated in the submucosa principally suppresses 5-HT-evoked Cl⁻ secretion.

The serosal addition of the NO donor SNAP increased basal $I_{\rm sc}$, whereas the luminal addition of SNAP (0.1 or 1 mM) decreased $I_{\rm sc}$ in mucosa-submucosa preparations, consistent with NO inhibiting anion secretion in proximal colonic mucosa rather than in the submucosa (Figure 8C). Luminal 5-HT-evoked $I_{\rm sc}$ gradually returned to basal values after the luminal addition of SNAP in a dose-dependent manner (Figure 8D). SNAP (1 mM) treatment decreased 5-HT-evoked $I_{\rm sc}$ by 48%. These results suggest that submucosa-derived NO suppresses luminal 5-HT-evoked anion secretion.

Selective inhibitors for NOS1 (NPA, $10\,\mu\text{M}$) and NOS2 (1400W, $10\,\mu\text{M}$), and the relatively selective inhibitor for NOS3 (L-NIO, $100\,\mu\text{M}$), were used to identify the predominant anti-secretory NOS isoform. The inhibitor concentrations used were chosen based on the concentrations used in earlier studies conducted in comparable preparations (MacEachern *et al.*, 2011). Serosal NPA or 1400W, but not L-NIO, significantly enhanced the response to luminal 5-HT (Figure 8E), indicating that submucosal NOS1 and NOS2 primarily affected 5-HT-evoked anion secretion.

The downstream pathway of NO was investigated to confirm the inhibitory effect of NO signalling on luminal 5-HT-evoked secretion in mucosa-submucosa preparations. We used the soluble GC (sGC) inhibitor NS-2028 (10 μ M) and the cGMP-dependent PK (PKG) inhibitor KT-5823 (10 μ M), which inhibits NO- and cGMP-induced ion transport, respectively, at this concentration (Cho *et al.*, 1999; Stoner and Kellum, 2001). Luminal application of NS-2028 did not alter basal $I_{\rm sc}$, but significantly enhanced the response to luminal 5-HT (Figure 8F). The basal $I_{\rm sc}$ or luminal 5-HT-evoked $I_{\rm sc}$ increase was not altered by pretreatment with KT-5823 in the serosal and luminal baths (Figure 8G). These results suggest that NO suppresses the luminal 5-HT-evoked secretion via sGC activation, but independent of PKG activation.





Comparison of luminal 5-HT-evoked increase in I_{sc} with or without submucosa present. (A) Dose dependency of 5-HT-evoked ΔI_{sc} in mucosasubmucosa or mucosal preparations. 5-HT was cumulatively added into the luminal bath and ΔI_{sc} was determined as the difference from basal I_{sc} . There were significant differences between the two types of preparation (F = 53.3) and among 5-HT concentrations (F = 25.4) by two-way ANOVA. n = 5. *P < 0.05. (B) A representative trace of I_{sc} in the mucosal preparation illustrated that luminal application of 5-HT increased I_{sc} in a stepwise manner. Further addition of bumetanide followed by acetazolamide returned I_{sc} to basal level. (C) Inhibitory rates of 5-HT (100 μ M)-evoked ΔI_{sc} by bumetanide and acetazolamide. (D) Bumetanide- or acetazolamide-sensitive I_{sc} portions of luminal 5-HT-evoked ΔI_{sc} . n = 6. *P < 0.05 versus mucosa-submucosa preparations.

Segmental differences in effect of luminal 5-HT in rat colon

As the secretory response to luminal compounds varies by colonic segment (Nobles *et al.*, 1991; Kaji *et al.*, 2012), we next investigated the segmental differences in the response to luminal 5-HT and the contribution of NO. In the presence of indomethacin and TTX, luminal 5-HT (100 μ M) increased I_{sc} in all colonic segments with a decreasing gradient from proximal to distal (Figure 9A). Unlike the proximal colon, L-NAME treatment failed to enhance the response to luminal 5-HT in the mid or distal colon (Figure 9B), indicating that NO-sensitive secretory pathway was restricted to the proximal colon.


Effect of amiloride on luminal 5-HT-evoked I_{sc} in rat colon

As an I_{sc} increase could be also generated by cation absorption, we next investigated the involvement of the ENaC channel on luminal 5-HT-evoked I_{sc} increases using the semi-selective ENaC inhibitor amiloride (100 μ M). Pretreatment

with luminal amiloride decreased basal $I_{\rm sc}$ by 3.2 \pm 0.6 μ A·cm⁻² (n = 5) in the distal colon, but had no effect in the mid and proximal colon. Luminal 5-HT (100 μ M)-evoked $I_{\rm sc}$ increases were significantly enhanced by amiloride in all colonic segments with no segmental difference, rather than inhibiting 5-HT-evoked $I_{\rm sc}$ increase (Figure 9C), suggesting that 5-HT-evoked $I_{\rm sc}$ increase is not due to Na⁺ absorption, whereas inhibition of ENaC enhances 5-HT-induced anion secretion by uncertain mechanisms.

Effects of luminal 5-HT on colonic HCO₃⁻ secretion in vivo

In order to confirm our assumption that luminal 5-HT stimulates colonic HCO $_3^-$ secretion, colonic HCO $_3^-$ secretion was measured with pH and CO $_2$ electrodes in a proximal colonic loop in anaesthetized rats. Colonic HCO $_3^-$ secretion expressed as total CO $_2$ output was stable during perfusion with pH 7.0 Krebs buffer (Figure 10). Luminal perfusion of 5-HT (100 $\mu M)$ significantly increased the rate of total CO $_2$ output, abolished by co-perfusion with GR113808 (10 $\mu M)$, but not by ondansetron (10 $\mu M)$.



Inhibition of 5-HT-evoked l_{sc} increases by NO signalling. (A, B) Effect of L-NAME on luminal 5-HT-evoked Δl_{sc} in mucosa-submucosa (A) or mucosal (B) preparations. L-NAME was added to the serosal bath 20 min before the application of 5-HT (100 μ M). n=5. *P<0.05 versus 5-HT group. (C) Effects of SNAP on basal l_{sc} in the presence of TTX and indomethacin in mucosa-submucosa preparations. There were significant differences among the groups (F=5.61 by one-way ANOVA). n=5. *P<0.05 versus 0.1 mM (S). (D) A representative l_{sc} trace in mucosa-submucosal preparation illustrated that luminal 5-HT increased l_{sc} and further addition of luminal SNAP decreased the 5-HT-evoked l_{sc} . (E) Effects of selective NOS isozyme inhibitors on luminal 5-HT-evoked Δl_{sc} in mucosa-submucosa preparations. The selective inhibitor for NOS1 NPA (10 μ M), for NOS2 1400W (10 μ M) or for NOS3 L-NIO (100 μ M) was added into the serosal bath 20 min before the application of 5-HT (100 μ M). There were significant differences among groups (F=3.24 by one-way ANOVA). n=6 for inhibitors, n=15 for control. *P<0.05 versus 5-HT group. (F) Effect of the sGC inhibitor on response to luminal 5-HT. NS-2028 (10 μ M) was added into the luminal bath 10 min before the application of 5-HT (100 μ M). n=5. *P<0.05 versus 5-HT group. (G) Effect of PKG inhibitor on response to luminal 5-HT. KT-5823 (10 μ M) was added into the serosal and luminal baths 10 min before the application of 5-HT (100 μ M). n=6.

Expression of 5-HT₃ and 5-HT₄ receptors in the colonic mucosa

We tested the hypothesis that the segmental heterogeneity in luminal 5-HT-induced I_{sc} changes would reflect the heterogeneity of 5-HT₄ receptor expression, and that 5-HT₄ receptors are localized on the apical membrane of rat proximal colon.

Real-time RT-PCR results confirmed that 5-HT_4 receptors were predominantly expressed in the colonic mucosa, compared with the expression of 5-HT_3 receptors, with significantly higher expression in the proximal colonic mucosa than in the mid or distal colonic mucosa (Figure 11A). In contrast, 5-HT_3 receptors were highly expressed in the submucosal






Figure 9

Segmental heterogeneity of 5-HT-evoked I_{sc} increases in rat colon. (A) 5-HT (100 μ M) was added to the luminal bath with ΔI_{sc} measured in mucosa-submucosa preparations of proximal, mid or distal colon. There were significant differences (F=10.5 by one-way ANOVA). n=5. *P<0.05 versus proximal colon. (B, C) Luminal 5-HT-evoked ΔI_{sc} was measured in the presence or absence of L-NAME (0.1 mM, B) or amiloride (0.1 mM, C). L-NAME was added into the serosal bath, whereas amiloride was added into the luminal bath 20 min before the application of 5-HT (100 μ M). There were significant differences among segments (B: F=27.7, C: F=3.78) and between treatment groups (B: F=14.0, C: F=61.1) as detected by two-way ANOVA. n=5. *P<0.05 versus 5-HT group in each segment, *P<0.05 versus proximal colon in each treatment group.

layer without segmental differences (Figure 11B). 5-HT_4 receptors were also equally expressed in the submucosa across the segments. These results support our hypothesis that segmental differences in the 5-HT_4 -mediated secretory response to luminal 5-HT correspond to segmental differences in 5-HT_4 receptor expression.

In histological sections of proximal colon, the 5-HT_4 receptor was immunolocalized to the epithelial cells, especially the apical membrane (Figure 11C), whereas preabsorption of 5-HT_4 antibody by immunized peptide abolished the staining (Figure 11D). These results suggest the functional expression of 5-HT_4 receptor on the apical membrane, consistent with luminal 5-HT_4 -induced signal inhibited by luminal 5-HT_4 receptor antagonism.

Expression of NOS isozymes in the submucosal layer

Immunohistochemistry of whole-mount submucosal preparations of rat proximal colon localized NOS-1-positive neurons to the submucosal plexus, confirmed with the neural

marker PGP9.5 (Figure 12A–C). In contrast, NOS-2 was located in GFAP-positive glial cells surrounding submucosal neurons (Figure 12D–F). No colocalization of NOS1 with NOS2 was observed in the submucosal preparations (Figure 12G–I).

Discussion

We have demonstrated that luminal 5-HT-evoked anion secretion, which was predominantly HCO_3^- secretion in the proximal colon, was mediated by 5-HT₄ receptor activation, independent of neural and COX pathways. Furthermore, 5-HT-evoked anion secretion was enhanced by the removal of submucosa or by NOS inhibition. NO release followed by sGC activation suppressed luminal 5-HT-evoked Cl⁻ secretion. $I_{\rm sc}$ responses to luminal 5-HT occurred predominantly in the proximal colon rather than in the mid and distal colon. Our findings indicate that a novel luminal 5-HT₄-mediated HCO_3^- secretory pathway and a submucosal inhibitory pathway are present in the rat proximal colon.




Figure 10

Effect of luminal perfusion of 5-HT on colonic HCO_3^- secretion *in vivo*. HCO_3^- secretory rate was measured as total CO_2 output by flow-through pH and CO_2 electrodes. The proximal colonic loop was perfused with 5-HT from t = 10 min with or without ondansetron or GR113808. n = 6. *P < 0.05 versus pH 7.0 Krebs group, †P < 0.05 versus 5-HT group. There were significant differences among time points (F = 39.8) and between treatment groups (F = 14.6) as detected by two-way ANOVA.

One of the well-studied 5-HT receptor subtypes, 5-HT₄, which is ubiquitously and abundantly expressed in the plasma membrane of colonocytes, has protective functions, including the attenuation of visceral hypersensitivity and the augmentation of mucus and anion secretion (Hoffman et al., 2012), consistent with our data. Immunolocalized to the apical membrane of the proximal colonic epithelial cells, 5-HT₄ receptors mediated HCO₃⁻ secretion in vitro (in Ussing chamber preparations) and in vivo, in response to luminal 5-HT, cisapride or tegaserod. These studies indicate that functional 5-HT₄ receptors are present on the apical membrane of the epithelial cells lining rat proximal colon, whereas other colonic segments were less responsive to luminal 5-HT, paralleled by higher expression of 5-HT₄ receptor in the proximal in comparison with the mid and distal colonic segments according to real-time RT-PCR. Although the contribution of 5-HT₃ receptors to GI function is well known, the expression of 5-HT₃ receptors was relatively low in scraped colonic mucosa in all segments, but high in the submucosal layer. These results suggest disparate functions for the 5-HT₄ and 5-HT₃ receptors in the mucosa and in the submucosa respectively.

Luminal 5-HT- or 5-HT₄ agonist-evoked *I*_{sc} increases were not affected by TTX or by atropine in muscle-stripped preparations of rat proximal colon. In contrast, luminal tegaserod in whole-mounted mouse distal colon increased I_{sc} via a TTXsensitive pathway (Hoffman et al., 2012), suggesting that the myenteric plexus might be involved in luminal 5-HT-evoked anion secretion. The rat caecum is a major site of bacterial fermentation, producing high luminal concentrations of SCFAs to which the cecal mucosa is constantly exposed, although the pH of luminal content is maintained at ~7 throughout the caudad large intestine (Annison et al., 2003). Our data thus support the hypothesis that luminal pH is maintained by HCO₃⁻ secretion in the proximal colon. Proximal region-specific electrogenic HCO₃⁻ secretion is likely to be mediated by the cystic fibrosis transmembrane conductance regulator (CFTR) anion channel, which is expressed in

the caecum and proximal colon, but not in the distal colon (Jakab *et al.*, 2011). Yet, none of the available CFTR inhibitors, such as CFTR_{inh}-172, glibenclamide or PPQ102, had any effect on 5-HT-evoked *I*_{sc} increases in the Ussing chamber studies (data not shown). Because Cl⁻ depletion reduced the response to luminal 5-HT to a greater extent than NKCC1 inhibition, a Cl⁻-dependent HCO₃⁻ secretion pathway may be present. The anion exchanger SLC26A3 (down-regulated in adenoma; DRA) is likely to contribute to colonic HCO₃⁻ secretion (Talbot and Lytle, 2010). Still, DRA, an exchanger whose electrogenicity has not been confirmed in intact tissues, is highly expressed in the distal, but not in the proximal colon. Therefore, the identity of the 5-HT-induced electrogenic HCO₃⁻ transporter or channel remains to be clarified.

Our results are also consistent with the presence of a negative feedback system provided by SERT expressed on the luminal and serosal poles of enterocytes and on subepithelial tissues. The presence of a 5-HT reuptake mechanism on the luminal pole underscores the importance of luminal 5-HT signalling, perhaps for luminal pH homeostasis, at least in the proximal colon. Similarly, 5-HT is released into the duodenal lumen in response to acid exposure (Kellum *et al.*, 1983; Smith *et al.*, 2006), suggesting that luminal 5-HT signalling may protect the mucosa from acid injury.

We demonstrated that L-NAME treatment increased luminal 5-HT-evoked anion secretion in mucosa-submucosa preparations, consistent with the anti-secretory effect of NO. The prosecretory effect of luminal 5-HT and the inhibitory effect of NO were significantly greater in the proximal colon compared with mid and distal colon, again indicating the segmental heterogeneity of colonic HCO₃⁻ secretion. Furthermore, luminal addition of the NO donor SNAP decreased basal and 5-HT-evoked secretion in the presence of TTX and indomethacin. Consistent with our results, cAMP-dependent anion secretion is attenuated by endogenous NOS2-derived NO, accumulated in the presence of inflammation or radiation (Asfaha *et al.*, 1999; Freeman and MacNaughton, 2000; MacEachern *et al.*, 2011). In the mouse distal colon, myen-






Figure 11

Expression of 5-HT₃ and 5-HT₄ receptors in rat colonic mucosa. (A) mRNA expression levels of 5-HT₃ and 5-HT₄ in the scraped colonic mucosa were compared among proximal (PCm), mid (MCm) and distal (DCm) segments. There were significant differences among colonic segments (F = 9.25) and between 5-HT₃ and 5-HT₄ (F = 75.3) as detected by two-way ANOVA. *P < 0.05 versus 5-HT₃ in the corresponding segment, †P < 0.05 versus proximal colon in each receptor group. (B) mRNA expression levels of 5-HT₃ and 5-HT₄ in the submucosa were compared among proximal (PCsm), mid (MCsm) and distal (DCsm) segments. There was no significant difference among colonic segments (F = 0.72) whereas there was significant difference between 5-HT₃ and 5-HT₄ (F = 17.3) as detected by two-way ANOVA. *P < 0.05 versus 5-HT₃ in the corresponding segment. (C) Immunoreactivity for 5-HT₄ receptor (green, arrows) was localized on the apical membrane of surface epithelial cells in the proximal colonic mucosa, but not of the goblet cells (*). Nuclei were counterstained with 4',6-diamidino-2-phenylindole (blue). (D) Lack of immunoreactivity with pre-incubated 5-HT₄ antibody with antigen peptide. L, lumen. Bar = 20 μ m.

teric ganglia decrease cholinergic secretion via NOS1- and NOS2-derived NO (MacEachern et al., 2011). In contrast, serosal 5-HT-evoked secretion is partly mediated by NO in Ussing-chambered colon (Kadowaki et al., 1996; Stoner et al., 2000). Serosal NO, exogenously generated by sodium nitroprusside (SNP) stimulated colonic anion secretion depending on neural and COX activation pathways (Tamai and Gaginella, 1993; Wilson et al., 1993). As the removal of the submucosa mimicked the effect of NOS inhibition, endogenous NO is probably released by the submucosal compartment under basal conditions. We provided data supporting the distinct expression of NOS1 and NOS2 in the submucosal plexus of rat proximal colon. Consistent with previous reports, NOS1 was localized to submucosal neurons (Ekblad et al., 1994) with NOS2 localized to the enteric glia (Green et al., 2004). NOS3 is normally ubiquitously expressed in the

vascular endothelium of submucosa (Takahashi *et al.*, 1997), although a NOS3 inhibitor had no effect on luminal 5-HT-evoked anion secretion. Taken together, these results suggest that the effects of NO will vary according to cell type, location and physiological/pathological concentrations.

Although inhibition of sGC enhanced luminal 5-HT-evoked secretion, the inhibition of its downstream enzyme PKG had no effect, indicating that NO suppressed anion secretion via cGMP production without PKG activation. Incubation with SNP increases intracellular cGMP in colonic enteric neurons and in the subepithelial compartment, but not in the epithelial cells (Young *et al.*, 1993; Wilson *et al.*, 1996). These reports indicate that NO-sensitive sGC is predominantly present in the neurons and subepithelial tissues, not in the colonocytes. Therefore, submucosa-derived NO might increase cGMP via sGC in the neurons or in the sub-




Figure 12

Localization of NOS isoforms in submucosa of rat proximal colon. (A–F) Double immunostaining for a neural marker PGP9.5 (red, A) with NOS1 (green, B), or a glial marker GFAP (green, D) with NOS2 (red, E) in whole-mount preparations of submucosa. Colocalization appeared as yellow (C, F). (G–I) Double immunostaining for NOS2 (green, G) and NOS1 (red, H) revealed lack of colocalization (I). Bar = 50 μm.

epithelial tissues, inhibiting luminal 5-HT-evoked Cl^- secretion independently of PKG. ENaC inhibition with amiloride also enhanced luminal 5-HT-evoked anion secretion in all colonic regions, suggesting that ENaC activity might 'mask' anion secretion-dependent I_{sc} changes. These findings suggest that luminal 5-HT-evoked secretory responses may be modulated by a variety of epithelial and subepithelial signal

transmitters which balance the physiological and pathological states.

In conclusion, luminal 5-HT stimulated HCO₃⁻ secretion via activation of apical 5-HT₄ receptors, whereas 5-HT-induced Cl⁻ secretion was suppressed by NO generated in the submucosa of the proximal colon. Our findings suggest that luminal 5-HT release due to luminal acidic pH as a result of



high SCFA concentrations followed by HCO₃⁻ secretion may be important for maintenance of mucosal integrity by regulating luminal pH near 7.

Acknowledgements

The authors thank B. Palileo for preparing the manuscript. The helpful discussion of Dr E. Engel and Dr P. H. Guth is gratefully acknowledged. This study was supported by a Department of Veterans Affairs Merit Review Award, NIH-NIDDK R01 DK54221 (J. D. K.), and the animal core of NIH-NIDDK P30 DK0413 (J. E. Rozengurt).

Author contributions

I. K. and Y. A. were responsible for the design, acquisition and analysis of data, and preparation of the manuscript. H. S. and K. N. contributed to the acquisition of additional data. I. K., Y. A and J. D. K. contributed to the interpretation of data and to the editing of the manuscript.

Conflict of interest

The authors declare no conflicts of interest.

References

Ahlman H, Bhargava HN, Dahlstrom A, Larsson I, Newson B, Pettersson G (1981a). On the presence of serotonin in the gut lumen and possible release mechanisms. Acta Physiol Scand 112: 263–269.

Ahlman H, DeMagistris L, Zinner M, Jaffe BM (1981b). Release of immunoreactive serotonin into the lumen of the feline gut in response to vagal nerve stimulation. Science 213: 1254–1255.

Akiba Y, Furukawa O, Guth PH, Engel E, Nastaskin I, Kaunitz JD (2001). Acute adaptive cellular base uptake in rat duodenal epithelium. Am J Physiol Gastrointest Liver Physiol 280: G1083–G1092.

Akiba Y, Ghayouri S, Takeuchi T, Mizumori M, Guth PH, Engel E *et al.* (2006). Carbonic anhydrases and mucosal vanilloid receptors help mediate the hyperemic response to luminal CO₂ in rat duodenum. Gastroenterology 131: 142–152.

Akiba Y, Mizumori M, Guth PH, Engel E, Kaunitz JD (2007). Duodenal brush border intestinal alkaline phosphatase activity affects bicarbonate secretion in rats. Am J Physiol Gastrointest Liver Physiol 293: G1223–G1233.

Akiba Y, Watanabe C, Mizumori M, Kaunitz JD (2009). Luminal L-glutamate enhances duodenal mucosal defense mechanisms via multiple glutamate receptors in rats. Am J Physiol Gastrointest Liver Physiol 297: G781–G791.

Alexander PH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Catterall WA *et al.* (2013a). The Concise Guide to PHARMACOLOGY 2013/14: Ligand-gated Ion Channels. Br J Pharmacol 170: 1582–1606.

Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL Spedding M *et al.* (2013b). The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. Br J Pharmacol 170: 1459–1581.

Alexander PH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Catterall WA *et al.* (2013c). The Concise Guide to PHARMACOLOGY 2013/14: Ion Channels. Br J Pharmacol 170: 1607–1651.

Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M *et al.* (2013d). The Concise Guide to PHARMACOLOGY 2013/14: Transporters. Br J Pharmacol 170: 1706–1796.

Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M *et al.* (2013e). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797–1867.

Annison G, Illman RJ, Topping DL (2003). Acetylated, propionylated or butyrylated starches raise large bowel short-chain fatty acids preferentially when fed to rats. J Nutr 133: 3523–3528.

Asfaha S, Bell CJ, Wallace JL, MacNaughton WK (1999). Prolonged colonic epithelial hyporesponsiveness after colitis: role of inducible nitric oxide synthase. Am J Physiol 276: G703–G710.

Badria FA (2002). Melatonin, serotonin, and tryptamine in some Egyptian food and medicinal plants. J Med Food 5: 153–157.

Baker LP, Nielsen MD, Impey S, Metcalf MA, Poser SW, Chan G et al. (1998). Stimulation of type 1 and type 8 Ca^{2+} /calmodulin-sensitive adenylyl cyclases by the G_s -coupled 5-hydroxytryptamine subtype 5-HT_{7A} receptor. J Biol Chem 273: 17469–17476.

Bridges RJ, Rack M, Rummel W, Schreiner J (1986). Mucosal plexus and electrolyte transport across the rat colonic mucosa. J Physiol 376: 531–542.

Bunce KT, Elswood CJ, Ball MT (1991). Investigation of the 5-hydroxytryptamine receptor mechanism mediating the short-circuit current response in rat colon. Br J Pharmacol 102: 811–816.

Bülbring E, Lin RC (1958). The effect of intraluminal application of 5-hydroxytryptamine and 5-hydroxytryptophan on peristalsis; the local production of 5-HT and its release in relation to intraluminal pressure and propulsive activity. J Physiol 140: 381–407.

Cho MM, Ziats NP, Pal D, Utian WH, Gorodeski GI (1999). Estrogen modulates paracellular permeability of human endothelial cells by eNOS- and iNOS-related mechanisms. Am J Physiol 276: C337–C349.

Cremon C, Carini G, Wang B, Vasina V, Cogliandro RF, De GR *et al.* (2011). Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome. Am J Gastroenterol 106: 1290–1298.

Day J, King B, Haque SM, Kellum JM (2005). A nonneuronal 5-hydroxytryptamine receptor 3 induces chloride secretion in the rat distal colonic mucosa. Am J Surg 190: 736–738.

Ekblad E, Mulder H, Uddman R, Sundler F (1994). NOS-containing neurons in the rat gut and coeliac ganglia. Neuropharmacology 33: 1323–1331.

Forbes IT, Dabbs S, Duckworth DM, Jennings AJ, King FD, Lovell PJ *et al.* (1998). (R)-3,N-dimethyl-N-[1-methyl-3-(4-methyl-piperidin-1-yl) propyl]benzenesulfonamide: the first selective 5-HT $_7$ receptor antagonist. J Med Chem 41: 655–657.

Freeman SL, MacNaughton WK (2000). Ionizing radiation induces iNOS-mediated epithelial dysfunction in the absence of an inflammatory response. Am J Physiol Gastrointest Liver Physiol 278: G243–G250.



Fukumoto S, Tatewaki M, Yamada T, Fujimiya M, Mantyh C, Voss M *et al.* (2003). Short-chain fatty acids stimulate colonic transit via intraluminal 5-HT release in rats. Am J Physiol Regul Integr Comp Physiol 284: R1269–R1276.

Gershon MD, Tack J (2007). The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 132: 397–414.

Glisic R, Koko V, Todorovic V, Drndarevic N, Cvijic G (2006). Serotonin-producing enterochromaffin (EC) cells of gastrointestinal mucosa in dexamethasone-treated rats. Regul Pept 136: 30–39.

Green CL, Ho W, Sharkey KA, McKay DM (2004). Dextran sodium sulfate-induced colitis reveals nicotinic modulation of ion transport via iNOS-derived NO. Am J Physiol Gastrointest Liver Physiol 287: G706–G714.

Hoffman JM, Tyler K, MacEachern SJ, Balemba OB, Johnson AC, Brooks EM *et al.* (2012). Activation of colonic mucosal 5-HT₄ receptors accelerates propulsive motility and inhibits visceral hypersensitivity. Gastroenterology 142: 844–854.

Jakab RL, Collaco AM, Ameen NA (2011). Physiological relevance of cell-specific distribution patterns of CFTR, NKCC1, NBCe1, and NHE3 along the crypt-villus axis in the intestine. Am J Physiol Gastrointest Liver Physiol 300: G82–G98.

Kadowaki M, Gershon MD, Kuwahara A (1996). Is nitric oxide involved in 5-HT-induced fluid secretion in the gut? Behav Brain Res 73: 293–296.

Kaji I, Yasuoka Y, Karaki S, Kuwahara A (2012). Activation of TRPA1 by luminal stimuli induces EP₄-mediated anion secretion in human and rat colon. Am J Physiol Gastrointest Liver Physiol 302: G690–G701.

Kang S, Kang K, Lee K, Back K (2007). Characterization of tryptamine 5-hydroxylase and serotonin synthesis in rice plants. Plant Cell Rep 26: 2009–2015.

Kellum J, McCabe M, Schneier J, Donowitz M (1983). Neural control of acid-induced serotonin release from rabbit duodenum. Am J Physiol 245: G824–G831.

Kellum JM, Albuquerque FC, Stoner MC, Harris RP (1999). Stroking human jejunal mucosa induces 5-HT release and Cl- secretion via afferent neurons and 5-HT₄ receptors. Am J Physiol 277: G515–G520.

Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010). Animal research: Reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577–1579.

Ly D, Kang K, Choi JY, Ishihara A, Back K, Lee SG (2008). HPLC analysis of serotonin, tryptamine, tyramine, and the hydroxycinnamic acid amides of serotonin and tyramine in food vegetables. J Med Food 11: 385–389.

MacEachern SJ, Patel BA, McKay DM, Sharkey KA (2011). Nitric oxide regulation of colonic epithelial ion transport: a novel role for enteric glia in the myenteric plexus. J Physiol 589: 3333–3348.

Martel F, Monteiro R, Lemos C (2003). Uptake of serotonin at the apical and basolateral membranes of human intestinal epithelial (Caco-2) cells occurs through the neuronal serotonin transporter (SERT). J Pharmacol Exp Ther 306: 355–362.

McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573–1576.

Ning Y, Zhu JX, Chan HC (2004). Regulation of ion transport by 5-hydroxytryptamine in rat colon. Clin Exp Pharmacol Physiol 31: 424–428.

Nobles M, Diener M, Rummel W (1991). Segment-specific effects of the heat-stable enterotoxin of E. coli on electrolyte transport in the rat colon. Eur J Pharmacol 202: 201–211.

Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP *et al*; NC-IUPHAR. (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098–D1106.

Sjölund K, Sandén G, Håkanson R, Sundler F (1983). Endocrine cells in human intestine – an immunocytochemical study. Gastroenterology 85: 1120–1130.

Smith AJ, Chappell AE, Buret AG, Barrett KE, Dong H (2006). 5-Hydroxytryptamine contributes significantly to a reflex pathway by which the duodenal mucosa protects itself from gastric acid injury. FASEB J 20: 2486–2495.

Stoner MC, Kellum JM (2001). Both serotonin and a nitric-oxide donor cause chloride secretion in rat colonocytes by stimulating cGMP. Surgery 130: 236–241.

Stoner MC, Scherr AM, Lee JA, Wolfe LG, Kellum JM (2000). Nitric oxide is a neurotransmitter in the chloride secretory response to serotonin in rat colon. Surgery 128: 240–245.

Takahashi M, Fukuda K, Ohata T, Sugimura T, Wakabayashi K (1997). Increased expression of inducible and endothelial constitutive nitric oxide synthases in rat colon tumors induced by azoxymethane. Cancer Res 57: 1233–1237.

Talbot C, Lytle C (2010). Segregation of Na/H exchanger-3 and Cl/HCO_3 exchanger SLC26A3 (DRA) in rodent cecum and colon. Am J Physiol Gastrointest Liver Physiol 299: G358–G367.

Tamai H, Gaginella TS (1993). Direct evidence for nitric oxide stimulation of electrolyte secretion in the rat colon. Free Radic Res Commun 19: 229–239.

Tsukamoto K, Ariga H, Mantyh C, Pappas TN, Yanagi H, Yamamura T *et al.* (2007). Luminally released serotonin stimulates colonic motility and accelerates colonic transit in rats. Am J Physiol Regul Integr Comp Physiol 293: R64–R69.

Wade PR, Chen J, Jaffe B, Kassem IS, Blakely RD, Gershon MD (1996). Localization and function of a 5-HT transporter in crypt epithelia of the gastrointestinal tract. J Neurosci 16: 2352–2364.

Wilson KT, Xie Y, Musch MW, Chang EB (1993). Sodium nitroprusside stimulates anion secretion and inhibits sodium chloride absorption in rat colon. J Pharmacol Exp Ther 266: 224–230.

Wilson KT, Vaandrager AB, De VJ, Musch MW, De Jonge HR, Chang EB (1996). Production and localization of cGMP and PGE_2 in nitroprusside-stimulated rat colonic ion transport. Am J Physiol 270: C832–C840.

Yang N, Liu SM, Zheng LF, Ji T, Li Y, Mi XL *et al.* (2010). Activation of submucosal 5-HT₃ receptors elicits a somatostatin-dependent inhibition of ion secretion in rat colon. Br J Pharmacol 159: 1623–1625.

Young HM, McConalogue K, Furness JB, De VJ (1993). Nitric oxide targets in the guinea-pig intestine identified by induction of cyclic GMP immunoreactivity. Neuroscience 55: 583–596.

Zhang JY, Nawoschik S, Kowal D, Smith D, Spangler T, Ochalski R *et al.* (2003). Characterization of the 5-HT₆ receptor coupled to Ca²⁺ signaling using an enabling chimeric G-protein. Eur J Pharmacol 472: 33–38.